Viewing nowJanudy 100 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 113.37mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

MFDS item code 202102956 · Approved 2021.04.06 · Insurance code 643705170
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It can also be administered as monotherapy; however, it can be combined with metformin in patients who have not previously used diabetes medications or have difficulty controlling blood sugar with monotherapy. Additionally, if monotherapy with sulfonylureas, metformin, thiazolidinediones, or insulin is insufficient to control blood sugar, this medication may be used in combination. It is also added to therapies involving multiple drugs when blood sugar control is difficult, enhancing therapeutic effects. By using various treatment methods in conjunction, it aids in improving blood sugar control.
This medication is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dosage adjustment based on renal function is required, evaluation of renal function is recommended before starting this medication and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered regardless of the timing of dialysis.
This medication may cause serious allergic reactions in some patients; if symptoms such as skin rash or difficulty breathing occur after administration, discontinue use immediately and consult a physician. This medication may cause pancreatitis, a condition in which inflammation occurs in the pancreas; therefore, if symptoms such as abdominal pain, nausea, or vomiting occur during use, visit a healthcare facility immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Patients who have had allergic reactions to this medication or its components should not use it. Patients with impaired kidney function may need dosage adjustments, and it is important to undergo regular kidney function tests. This medication carries a risk of hypoglycemia, especially when used in conjunction with insulin or sulfonylureas, so symptoms of hypoglycemia should be closely monitored. Some patients may experience side effects such as headache, upper respiratory infection, nasopharyngitis, diarrhea. If symptoms such as severe joint pain or skin blistering occur, inform a doctor immediately and discontinue use of the medication. Women who are pregnant or breastfeeding are advised not to take this medication. This medication generally has fewer interactions when combined with other drugs; however, it is best to consult a physician or pharmacist when taking it with specific drugs. In the case of overdose, immediate medical attention should be sought, and some may be removed via dialysis. Elderly patients may have decreased kidney function, necessitating dosage adjustments and monitoring.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to prevent exposure to air and moisture, and it is best to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will maintain the medication's efficacy and prevent deterioration.
Bright yellow-orange round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.37mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.